INDIA LIVE DESKNIFTY 50:23,140.50(+0.34%)SENSEX:73,895.74(+0.43%)
RDU Global
🇮🇳
Home/Topics/Companies & Institutions/Tatva Chintan Pharma Chem
Back to Newsroom
🏢Organization Dossier

Tatva Chintan Pharma Chem

Curated news coverage, institutional background, regulatory filings, and investigative reporting across RDU Global.

10 Stories Indexed
Last Updated: Just Now
Verified Entity Intelligence
Markets, IPOs & Wealth 08 Oct 2026, 05:49 AM IST

Valiant Organics Leads Five Commodity Stocks to 52-Week Highs as Sensex Slips

Five stocks in the BSE Commodities Index touched fresh 52-week highs on Wednesday even as the broader market weakened, underscoring selective buying in chemicals and specialty materials. Valiant Organics led the advance, with gains across the group ranging up to 48% over the past month, highlighting strong momentum in a narrow pocket of the market.

By RDU Global Wire5 min read
National Governance & Policy07 Oct 2026, 08:21 PM IST

PMGSY Chintan Shivir Sets Roadmap for Quality, Maintenance and Technology-Driven Rural Connectivity

A high-level Chintan Shivir on the Pradhan Mantri Gram Sadak Yojana has outlined a forward-looking agenda centered on construction quality, long-term maintenance and the use of technology in rural road delivery. The deliberations signal a shift from rapid network expansion toward durable, data-led connectivity that can better serve India’s villages over time.

5 min readRead →
Banking, Fintech & Insurance05 Oct 2026, 08:56 AM IST

IT Valuations Already Reflect Most AI Risk, Says ICICI Prudential’s Chintan Haria

The sharp correction in Indian IT stocks may already have absorbed much of the market’s fear over artificial intelligence-led disruption, according to Chintan Haria of ICICI Prudential AMC. He said the Nifty IT index’s roughly 25% decline in 2026 has created selective opportunities in companies better placed to benefit from data engineering, cloud migration, legacy modernisation and AI integration.

5 min readRead →
Banking, Fintech & Insurance05 Oct 2026, 08:32 AM IST

IT Valuations Already Price in Much of AI Risk, Says ICICI Prudential’s Chintan Haria

The sharp correction in Indian information technology stocks may already reflect a large part of the market’s anxiety over artificial intelligence-led disruption, according to Chintan Haria of ICICI Prudential AMC. He said the Nifty IT index’s roughly 25% decline in 2026 has created selective opportunities in companies better placed to benefit from data engineering, cloud migration, legacy modernisation and AI integration.

5 min readRead →
Markets, IPOs & Wealth17 Nov 2026, 02:00 PM IST

Sun Pharma Shares Track Market Mood as Investors Reprice Pharma Risk and Growth

Sun Pharmaceutical Industries’ share price was in focus in afternoon trade as investors weighed the stock’s near-term momentum against broader market cues, sector rotation, and expectations around earnings visibility. The move comes at a time when large-cap pharmaceutical counters remain sensitive to global demand trends, pricing pressure in key export markets, and domestic risk appetite.

5 min readRead →
Markets, IPOs & Wealth17 Nov 2026, 02:00 PM IST

Dr. Reddy’s Shares Edge Higher in Cautious Trade as Investors Reassess Pharma Valuations

Dr. Reddy’s Laboratories saw a modest uptick in its share price in afternoon trade, reflecting a measured rebound in a sector that has been under close scrutiny for pricing, earnings visibility and export demand. The move was not dramatic, but it signalled that investors remain willing to accumulate quality pharmaceutical names on dips even as broader market sentiment stays selective.

5 min readRead →
Global Markets & Equities05 Nov 2026, 08:00 PM IST

Boehringer Returns to Sino Biopharma in $7.4 Billion Cancer Pact

Boehringer Ingelheim has struck a new oncology partnership with Sino Biopharma, reviving a relationship that now carries a headline value of up to $7.4 billion. The deal centers on preclinical bispecific T-cell engagers and antibody-drug conjugates, underscoring how large drugmakers are still willing to pay for early-stage cancer assets with long-dated optionality. The agreement adds another major cross-border licensing transaction to a market already defined by capital discipline, pipeline replenishment and intense competition for differentiated oncology platforms. For investors, the structure signals both the scale of demand for next-generation cancer modalities and the long development runway that will determine how much of the deal value ultimately becomes payable.

6 min readRead →
Markets, IPOs & Wealth05 Nov 2026, 02:00 PM IST

Sun Pharma Shares in Focus as Traders Track Current Price Action Amid Broader Market Caution

Sun Pharmaceutical Industries Ltd. is drawing close market attention as investors monitor its live share price against a backdrop of cautious trading across Indian equities. The stock’s movement is being read not just as a company-specific signal, but also as a gauge of sentiment toward large-cap healthcare names in a volatile macro environment. With fiscal and macroeconomic cues still shaping risk appetite, Sun Pharma’s current trading pattern is likely to remain under scrutiny from institutional and retail investors alike. Market participants are watching for whether the counter can sustain momentum, consolidate, or face pressure from broader sector rotation.

5 min readRead →
Healthcare, Pharma & Life Sciences01 Nov 2026, 02:00 PM IST

Sun Pharma Q2 Profit Falls 36% as Litigation and Deal Costs Weigh on Earnings

Sun Pharmaceutical Industries reported a 36% drop in second-quarter net profit to Rs 1,989 crore, as exceptional litigation and acquisition-related expenses sharply reduced earnings. Revenue rose 11.8% on the back of strong domestic and emerging-market demand, but weakness in the US formulations business tempered the overall performance.

4 min readRead →
Global Markets & Equities17 Oct 2026, 08:00 AM IST

Epic Unites Amazon Pharmacy, LillyDirect and Mark Cuban in Drug Price Tool Push

Epic Systems is launching a prescription drug pricing tool with Amazon Pharmacy, LillyDirect and Mark Cuban’s Cost Plus Drugs, aiming to give patients cash-price comparisons before they leave the doctor’s office. The move could sharpen competition in retail pharmacy and drug distribution while advancing a broader push for price transparency in U.S. healthcare.

5 min readRead →

🏢 About this Entity

Corporations, startups, regulatory bodies, central banks, ministries and judicial courts. All news mentioning this entity is automatically verified and aggregated into this live intelligence dossier.

Co-Occurring Entities

Entities frequently referenced alongside Tatva Chintan Pharma Chem: